Responses
Clinical and epidemiological research
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
Compose a Response to This Article
Other responses
No responses have been published for this article.